<DOC>
	<DOCNO>NCT02993029</DOCNO>
	<brief_summary>Osteoarthritis ( OA ) knee common form arthritis world1e , receive grow attention society increase old age population , disabled people , medical expense disease . 99Tc-MDP effective rheumatoid arthritis . Therefore , investigator try investigate effect 99Tc-MDP treatment patient osteoarthritis knee compare celecoxib .</brief_summary>
	<brief_title>99Tc-MDP Treatment Knee Osteoarthritis</brief_title>
	<detailed_description>The prevalence osteoarthritis knee ( OA ) increase worldwide burden continue increase owe age general population 99Tc-MDP effective rheumatoid arthritis . Consequent increase incidence rise number patient knee OA prone deterioration knee . It therefore important good understand , control , attempt prevent progression disease patient knee OA . Limitations walking , stair climbing , squat common patient complaint greatly interfere activity daily live recreation . Currently definite consensus standardize management OA . Oral analgesic anti-inflammatory agent perhaps commonly prescribed treatment alleviate knee OA symptom . The failure nonsurgical therapy modify quality life knee OA patient surprise give inability alleviate physical manifestation OA . Surgical knee OA intervention generally result good excellent patient outcome . However , significant barrier consider surgery , limit clinical utility . 99Tc-MDP actually decay product 99mTc-MDP ( 99mTc-methylene diphosphonate , US Food Drug Administration-approved radioactive agent widely use bone scintigraphy ) . 99Tc-MDP ( Chengdu Yunke Pharmaceutical , Sichuan , China ) kind anti-inflammatory drug patent China ( patent . ZL94113006.1 ) . It approve production State Food Drug Administration China October 1997 . 99Tc-MDP demonstrated safe effective clinical treatment immune disease , rheumatoid arthritis ( RA ) , ankylose spondylitis ( AS ) certain bone disease , skeletal metastasis cancer China . 99Tc-MDP also show clinical effect knee OA practice . Therefore , investigator try investigate effect 99Tc-MDP treatment patient osteoarthritis knee compare celecoxib .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>1 . Participants painful osteoarthritis ; 2 . The standard uptake value ( SUV ) OA relate knee great 10 18F sodium fluoride bone scan ; 3 . Participants voluntarily participate trial , sign informed consent . 1 . Knee joint replacement ; 2 . Inflammatory arthritis joint infection knee ; 3 . Nervous joint disease ; 4 . Fracture joint ; 5 . Gout arthritis knee ; 6 . Traumatic arthritis .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>99Tc-MDP</keyword>
	<keyword>osteoarthritis</keyword>
	<keyword>celecoxib</keyword>
</DOC>